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Abstract
Background: Cardiovascular events are the leading cause of death in end stage renal disease
(ESRD). Adherence to phosphate binding medication plays a vital role in reducing serum
phosphorus and associated cardiovascular risk. This poses a challenge for patients as the regimen
is often complex and there may be no noticeable impact of adherence on symptoms. There is a
need to establish the level of nonadherence to phosphate binding medication in renal dialysis
patients and identify the factors associated with it.
Methods: The online databases PsycINFO, Medline, Embase and CINAHL were searched for
quantitative studies exploring predictors of nonadherence to phosphate binding medication in
ESRD. Rates and predictors of nonadherence were extracted from the papers.
Results: Thirty four studies met the inclusion criteria. There was wide variation in reported rates
of non-adherence (22–74% patients nonadherent, mean 51%). This can be partially attributed to
differences in the way adherence has been defined and measured. Demographic and clinical
predictors of nonadherence were most frequently assessed but only younger age was consistently
associated with nonadherence. In contrast psychosocial variables (e.g. patients' beliefs about
medication, social support, personality characteristics) were less frequently assessed but were
more likely to be associated with nonadherence.
Conclusion: Nonadherence to phosphate binding medication appears to be prevalent in ESRD.
Several potentially modifiable psychosocial factors were identified as predictors of nonadherence.
There is a need for further, high-quality research to explore these factors in more detail, with the
aim of informing the design of an intervention to facilitate adherence.
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Cardiovascular events constitute the leading cause of
death in dialysis patients, accounting for nearly half of all
deaths [1]. The increased incidence of cardiac disease in
patients with end-stage renal disease (ESRD) has been
associated with hyperphosphatemia and more specifically
an elevated Calcium × Phosphate product [2], making
phosphate control an important goal of treatment. Three
strategies help to control serum phosphate in ESRD: dial-
ysis, diet restrictions and phosphate binding medication.
Adherence to phosphate binding medication may be a
particular challenge for dialysis patients, due to complex
treatment regimens that may have no noticeable effect on
symptoms. Many patients on dialysis are nonadherent
with phosphate binding medication [3] but the extent of
the problem and the reasons for it are poorly understood.
There is a current emphasis in the literature on the impor-
tance of facilitating adherence to medication in chronic
illnesses [4-6]. In order to develop a theory-based inter-
vention to optimise adherence to phosphate binding
medication, there is a need to first understand the factors
associated with nonadherence that could be addressed.
Previous reviews of predictors of adherence in ESRD have
tended to focus on other aspects of the regime (e.g. diet
and fluid restrictions, dialysis attendance) [7-10] and have
not used comprehensive systematic search strategies
[7,8,11]. This is the first paper to systematically search and
review the literature specifically relating to adherence to
phosphate binding medication.
The aims of this review were to assess the prevalence of
nonadherence to phosphate binding medication in
patients with ESRD and to identify factors associated with
low adherence.
Methods
Articles were identified for review through the search of
online databases PsycINFO (1967–2006), Medline
(1950–2006), Embase (1980–2006) and CINAHL
(1982–2006). Papers with abstracts containing a combi-
nation of three of the terms shown in Table 1 (one from
each column) were selected.
The database search resulted in the identification of 481
papers. Three additional papers were identified through a
reference list search. Each paper was evaluated by two
independent reviewers. Papers were retained if they con-
tained quantitative studies exploring predictors of nonad-
herence to PB medication in ESRD, were published in
English and were available from the British Library. Qual-
itative studies were excluded because this review aimed to
quantify the number of studies reporting a statistically sig-
nificant relationship versus the number of studies finding
no significant relationship between each possible predic-
tor of nonadherence and nonadherence. Papers were also
excluded if they focused on paediatric adherence (patients
under 18 years old), were review articles, intervention
studies or case studies, or contained secondary analyses
on data already included in this review.
The two reviewers extracted information on the rates of
nonadherence reported and the predictors of nonadher-
ence explored in each paper. A list of all the variables that
had been investigated in relation to nonadherence was
compiled. These possible predictors of nonadherence
were divided into three categories: demographic, clinical
and psychosocial. The number of studies reporting a sig-
nificant relationship (p < .05) between each variable and
nonadherence and the number of studies reporting no sig-
nificant relationship (p > .05) between each variable and
nonadherence were recorded.
Results and discussion
Thirty four studies fulfilled the inclusion criteria. Key
information extracted from these papers is presented in
Table 2.
Prevalence of nonadherence
Only 13 studies reported rates of nonadherence to phos-
phate binding medication. Estimates of the percentage of
nonadherent participants ranged from 22–74% (mean
51%). This variation can in part be attributed to differ-
ences in the way in which nonadherence was measured
and defined, for example, the mean number of people
classified as nonadherent when assessed through serum
phosphorus levels was 58%, compared to 31% when
assessed using self report measures.
These measurement issues are discussed in more detail
under limitations of the studies reviewed.
Predictors of nonadherence
Demographic variables
The most frequently assessed demographic predictors of
phosphate binder adherence were age (24 studies), gender
(22 studies), educational level (21 studies), marital status
(11 studies), ethnicity (8 studies), income (6 studies) and
employment status (3 studies). As shown in Figure 1, few
Table 1: Terms used in database searches ($ indicates 
truncation)
Haemodialysis Adheren$ Medication$
Hemodialysis Nonadheren$ Phosphate binder$
Uremic Complian$ Serum phosphate
Dialysis Noncomplian$ Serum phosphorus
Renal disease Regimen$
Note. The search term 'dialysis' retrieved studies involving 
participants receiving peritoneal dialysis, therefore the papers 
reviewed included participants receiving both peritoneal dialysis and 
hemodialyis.Page 2 of 10
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Study N 
Dialysis 
type
Mean 
age 
(years)
Mean 
time on 
dialysis 
(months)
Gender  
% male
Main 
statistical 
analysis
Predictors of adherence Adherence 
assessment
Non-
adherence 
definition
% Non-
adherent
Demographic Clinical Psychosocial
Bame et al, 1993 
U.S. [12]
1230 
HD
57 Not stated 47% Multiple 
logistic 
regression
Age*, income*, 
gender, 
ethnicity, 
marital status, 
education
Not 
assessed
Not assessed Serum 
phosphorus
>6 mg/dl 50%
Betts & Crotty, 
1988 U.S.[42]
46 HD Not 
stated
Not stated 33% Correlations Age, education Time on 
dialysis
Response to illness Serum 
phosphorus
> 5 mg/dl 74%
Blanchard et al, 
1990 U.S.[38]
40 HD 
40 PD
50 Not stated 48% Correlations Gender Time on 
dialysis
Not assessed Self report Reporting 
ever missing a 
dose
28%
Boyer et al, 1990 
U.S.[13]
60 HD Not 
stated
Not stated 71% Correlations
, multiple 
regression
Age*, marital 
status*, gender, 
ethnicity, 
income, 
education
Time on 
dialysis
Social support* Serum 
phosphorus
Not 
dichotomised
Not stated
Christensen et al, 
1994 U.S.[14]
52 HD 
34 PD
49 73 53% Hierarchical 
regression
Age**, gender, 
marital status, 
education
Diabetic 
status, time 
on dialysis, 
transplant 
history, type 
of dialysis
Information 
vigilance, active 
coping
Serum 
phosphorus
Not 
dichotomised
Not stated
Christensen et al, 
1995 U.S.[15]
72 HD 
or PD
46 73 54% Correlations
, stepwise 
regression
Age*, education Time on 
dialysis, 
transplant 
history
Neuroticism, 
extraversion, 
openness to 
experience, 
agreeableness, 
conscientiousness*
Serum 
phosphorus
Not 
dichotomised
Not stated
Christensen et al, 
1996a U.S.[44]
52 HD 59 62 59% Regression Age, education, 
gender
Diabetic 
status, time 
on dialysis
Neuroticism, 
private body 
consciousness, 
illness related 
physical impairment
Serum 
phosphorus
Not 
dichotomised
Not stated
Christensen et al, 
1996b U.S. [16]
67 HD 
14 PD
55 70 49% Regression Age **, 
education, 
gender
Diabetic 
status*, type 
of dialysis, 
time on 
dialysis
Perceived health 
competence*, 
health locus of 
control
Serum 
phosphorus
Not 
dichotomised
Not stated
Christensen et al, 
1997a U.S.[33]
51 HD 57 51 59% Correlation, 
hierarchical 
regression
Age, education, 
gender
Diabetic 
status, time 
on dialysis
Monitoring 
attentional style, 
trait anxiety, 
internal health locus 
of control, control 
appraisal, avoidant 
coping
Serum 
phosphorus
Not 
dichotomised
Not stated
Christensen et al, 
1997b U.S.[43]
48 HD 56 65 54% Correlations
, hierarchical 
regression
Age, education, 
gender
Diabetic 
status, time 
on dialysis
Cynical hostility*, 
health locus of 
control
Serum 
phosphorus
Not 
dichotomised
Not stated
Cummings et al, 
1982 U.S.[22]
116 HD 55 29 54% Correlations
, regression
Age*, gender, 
income, 
education
Time on 
dialysis, 
transplant 
history, 
regimen 
complexity*
Susceptibility, 
severity, benefits*+, 
barriers+, 
knowledge of 
purpose of 
regimen*, social 
support (family and 
friends), support 
from medical staff+, 
family problems+
Serum 
phosphorus 
Self report
>5.5 mg/dl 70% (based 
on serum 
phosphorus)
Curtin et al, 1999 
U.S.[49]
135 HD 63 Not stated 47% Chi-square Ethnicity###, 
age, gender, 
employment 
status, 
education
Cause of 
renal failure, 
no. 
comorbiditi
es, time on 
dialysis
Not assessed Electronic 
monitoring 
(used in 
analysis)
Pill count
Self report
Overdosing/
underdosing/
missing more 
than 20% 
prescribed 
doses
73% (based 
on 
electronic 
monitoring)
Eitel et al, 1998 
U.S.[27]
40 HD 
45 PD
55 40 61% Correlations Not assessed Not 
assessed
Efficacy 
expectations**, 
effort attributions, 
self control
Serum 
phosphorus 
(used in 
analysis)
Self report
Staff ratings
Not 
dichotomised
Not stated
Gago et al, 2000 
Spain[35]
121 HD 63 37 56% T-tests Gender, age, 
living 
arrangements
Cause of 
ESRD, time 
on dialysis
Knowledge Not clear Not clear 46%
Hilbert, 1985 
U.S.[29]
26 HD 47 54 35% Correlations
, ANOVA
Age, income, 
education, 
social class, 
religion, gender, 
significant other
No. times 
hospitalised, 
time on 
dialysis+
Directive guidance 
social support+, 
affection social 
support
Composite 
self report 
scale – 
adherence to 
medication, 
fluid and diet 
(used in 
analysis) 
Serum 
phosphorus
Not 
dichotomised
Not statedPage 3 of 10
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U.K.[17]
47 HD 49 53 49% Correlations Age+, gender, 
education
Duration of 
ESRD, time 
on dialysis, 
no. 
prescribed 
medicines
Beliefs about 
medication 
(concerns ++, 
perceived need, 
harm, overuse)
Self report Those who 
reported 
sometimes, 
often or very 
often 
deliberately 
missing a dose 
of their 
medication.
26%
Leggat et al, 1998 
U.S.[18]
6251 
HD
58 54 50% Logistic 
regression
Age***, 
ethnicity*, 
smoker*, 
gender, 
education, living 
arrangements
Time on 
dialysis, 
diabetic 
status, 
transplant 
history
Not assessed Serum 
phosphorus
>7.5 mg/dl 22%
Lin & Liang, 1997 
China[39]
86 HD 55 42 45% Correlations Not assessed Not 
assessed
Health locus of 
control+++, **
3 composite 
measures: 
Lab reports 
(including 
serum 
phosphorus)
Self report – 
fluid, diet and 
medication 
adherence
Nurses' 
assessment – 
fluid, diet and 
medication 
adherence
>4.59 mg/dl 61% (based 
on serum 
phosphorus)
Moran et al, 1997 
U.S.[45]
56 HD 57 46 64% Regression Age, gender, 
education
Time on 
dialysis, 
diabetic 
status, 
transplant 
history**
Social support, 
conscientiousness
Serum 
phosphorus
Not 
dichotomised
Not stated
Morduchowicz et 
al, 1993 
Israel[46]
50 HD 56 66 60% Multivariate 
and stepwise 
regression
Education ***, 
ethnicity*, 
gender, age, 
place of birth, 
religious 
observance, 
marital status, 
no. children, 
whether 
accompanied to 
session, 
economic 
status, living 
arrangements
Previous PD 
dialysis, time 
on dialysis
Not assessed Serum 
phosphorus
Not 
dichotomised
Not stated
O'Brien, 1980 
U.S.[28]
63 HD Not 
stated
Not stated 54% ANOVA, 
correlations, 
regression
Age, gender, 
marital status++, 
ethnicity, 
education, 
occupation, 
type of 
household
Time on 
dialysis
Significant others' 
expectations 
regarding 
adherence+++
Composite 
self report 
scale – 
dialysis 
attendance, 
diet, fluid and 
medication
Not stated Not stated
Reiss et al, 1986 
U.S.[47]
23 HD 48 8 57% Correlations Family income, 
marital status, 
years married, 
family size, 
education
Not 
assessed
Problem solving 
(coordination and 
closure), family 
intelligence
Serum 
phosphorus
Not 
dichotomised
Not stated
Schlebusch & 
Levin, 1982 
South Africa[34]
25 HD 
or PD
38 Not stated 48% Mann-
Whitney 
test
Not assessed Organicity 
(cortical 
dysfunction)
$
Intelligence, 
personality$$
Composite 
staff rating – 
including 
adherence to 
medication 
and diet
Not stated 44%
Schneider, 1992 
U.S.[19]
137 HD 51 26 54% Multiple 
regression
Age***, gender, 
ethnicity, 
education
Time on 
dialysis, 
frequency of 
physician 
contact
Health locus of 
control***
Serum 
phosphorus
Not 
dichotomized
Not stated
Sherwood, 1983 
U.S.[30]
55 HD 46 48 66% Correlations Not assessed Not 
assessed
Family 
understanding, 
family organisation*, 
supportive 
family**,+++
Serum 
phosphorus 
Composite 
self-report 
measure – 
diet, fluid and 
medication
Not stated Not stated
Stamatakis et al, 
1997 U.S.[20]
17 HD
4 PD
53 Not stated 48% Anova, chi-
square, 
multiple 
regression
Age*, gender, 
ethnicity 
education, 
occupation, 
marital status
Type of 
dialysis, 
cause of 
ESRD, 
transplant 
history
Knowledge* Serum 
phosphorus 
Self report
Not stated Not stated
Steidl et al, 1980 
U.S.[31]
22 HD
1 PD
43 22 57% Correlations Not assessed Medical 
assessment
Family 
functioning$$$
Composite 
staff 
assessment – 
dialysis 
attendance/
medication 
and diet 
adherence
Not stated Not stated
Takaki et al, 2003 
Japan[21]
484 HD 60 98 66% Correlations
, multiple 
regression
Age***, gender Time on 
dialysis***
Not assessed Serum 
phosphorus
Not 
dichotomised
Not stated
Table 2: Details of the studies included in the review (Continued)Page 4 of 10
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2004 U.S.[3]
129 HD 
59 PD
60 46 Not 
stated
ANOVA Age Time on 
dialysis, 
diabetic 
status, 
tablet 
burden*
Not assessed Self report
Serum 
phosphorus
Reporting 
taking less 
than 80% 
medication as 
prescribed
>5.5 mg/dl
38% (based 
on self 
report) 51% 
(based on 
serum 
phosphorus)
Tracy et al, 1987 
U.S.[40]
15 HD 52 0 (starting 
dialysis)
67% Correlations
, ANOVA
Not assessed Not 
assessed
Personality*, 
depression*, family 
environment
Composite 
measure – 
serum 
phosphorus 
and 
interdialytic 
weight
Not stated Not stated
Vives et al, 1999 
Spain[41]
31 HD 63 35 74% Mann 
Whitney, 
Wilcoxon, 
T-test
Age, gender Duration of 
treatment
Health locus of 
control
Composite 
score based 
on serum 
phosphorus, 
serum 
potassium 
and 
interdialytic 
weight
>6.01 mg/dl Not stated
Weed-Collins & 
Hogan, 1989 
U.S.[26]
30 HD Not 
stated
Not stated 43% Correlations Not assessed Not 
assessed
Knowledge of 
phosphate binders, 
susceptibility, 
severity, benefits, 
barriers*
Serum 
phosphorus
>5.5 mg/dl 64%
Wenerowicz et 
al, 1978 U.S.[37]
19 HD 36 7 68% Chi-square, 
t-test
Not assessed Not 
assessed
Health locus of 
control *
Serum 
phosphorus
>4.5 mg/dl 68%
Wiebe & 
Christensen, 
1997 U.S.[48]
70 HD 56 141 60% Stepwise, 
hierarchical 
regression
Age, gender, 
education, 
marital status
Diabetic 
status, time 
on dialysis
Conscientiousness, 
susceptibility, 
severity, benefits, 
barriers
Serum 
phosphorus
Not 
dichotomised
Not stated
Note: HD = hemodialysis, PD = peritoneal dialysis, ESRD = End stage renal disease
* p < 0.05 **p < 0.01 ***p < 0.001 relationship with serum phosphorus levels, + p < 0.05 ++p < 0.01 +++p < 0.001 relationship with self report adherence, # p < 0.05 ##p < 0.01 ###p < 0.001 
relationship with electronic monitoring, $p < 0.05 $$ < 0.01 $$$p < 0.001 relationship with staff ratings of adherence
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Demographic predictors of nonadherence to phosphate binding medication assessed by two or more studiesFigure 1
Demographic predictors of nonadherence to phosphate binding medication assessed by two or more studies.
0 5 10 15 20 25
Religion
Employment
Income
Ethnic group
Marital status/ living
arrangements
Education
Gender
Age
No. studies assessing each possible predictor of nonadherence
Not significant
Significant (p<.05)
BMC Nephrology 2008, 9:2 http://www.biomedcentral.com/1471-2369/9/2studies found significant relationships between demo-
graphic factors and adherence to phosphate binding med-
ication, with the exception of those exploring the impact
of age on adherence, where 11 of the 24 studies (46%)
exploring this variable found a significant result [12-22].
In these studies, older age was consistently associated with
higher levels of adherence. Suggested reasons for this find-
ing are that older people may be more concerned about
their mortality and have more structured lives in which to
accommodate the demands of the treatment regimen
[13], that younger patients may have more difficulty com-
ing to terms with having a chronic condition [13] or sim-
ply that younger patients are more willing to report
nonadherence than older patients [17].
Clinical variables
The most frequently assessed clinical predictors of nonad-
herence were length of time on hemodialysis (22 studies),
whether or not the patient was diabetic (9 studies) and the
patient's transplant history (i.e. whether or not they had
received a kidney transplant in the past; 6 studies). As
shown in Figure 2, none of these clinical variables were
consistently associated with adherence to phosphate
binding medication. Given the large tablet burden associ-
ated with phosphate binding medication (patients on
average take approximately eight phosphate binding tab-
lets per day [3]), it is surprising that only three studies
have explored the effects of regimen complexity on adher-
ence [3,17,22], with two finding significant results. One
found a correlation between complexity of the phosphate-
binding medicine regimen and serum phosphorus [22]
and one found that patients reporting low adherence and
those above target phosphorus levels were prescribed sig-
nificantly more phosphate binder pills per day [3].
Although high tablet burden may be a barrier to adher-
ence for many patients, we cannot assume a causal rela-
tionship between high tablet burden and low adherence
from these studies. One explanation is that high tablet
burden leads to low adherence, but an equally plausible
explanation is that low adherence results in poorer phos-
Clinical predictors of nonadherence to phosphate binding medication assessed by two or more studiesFigure 2
Clinical predictors of nonadherence to phosphate binding medication assessed by two or more studies.
0 5 10 15 20 25
Regimen complexity
Cause of ESRD
Type of dialysis
Transplant history
Diabetic status
Length of time on dialysis
No. studies assessing each possible predictor of nonadherence
Not significant
Significant (p<.05)Page 6 of 10
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tablets. A review across other therapeutic areas suggests
that prescribed number of doses is inversely related to
adherence [23] and this warrants further research in rela-
tion to phosphate binding medication. In addition, whilst
qualitative and descriptive studies have indicated that the
size and taste of the tablets may impact on adherence to
phosphate binding medication [24,25], none of the quan-
titative studies reviewed explored these variables. Further
research is needed to determine the role of these tablet-
related factors in predicting nonadherence.
Psychosocial variables
Whilst psychosocial predictors of nonadherence were the
least often assessed, they were more likely to be signifi-
cantly associated with nonadherence to phosphate bind-
ing medication than demographic and clinical variables
(see Figure 3).
Six of the nine studies investigating the relationship
between health beliefs and adherence to phosphate bind-
ing medication reported significant relationships. These
beliefs were all related to patients' perceptions of medica-
tion (e.g. concerns about potential adverse effects of med-
ication [17], perceived barriers to and benefits of taking
medication [22,26], perceptions of self efficacy with
regard to taking the medication [16,27] and perceptions
of others' expectations regarding adherence [28]). In a
recent review of adherence to medication across chronic
illnesses, such beliefs were identified as important poten-
tially modifiable predictors of nonaderence that could be
addressed within interventions to facilitate adherence [5].
Four of five studies found a relationship between social
support and adherence to phosphate binding medication.
This included support of friends and family [13,29,30]
and of renal staff [22]. In addition, three of five studies
exploring associations between family dynamics and
adherence reported significant results. Family problems
Psychosocial predictors of nonadherence to phosphate binding medication assessed by two or more studiesFigure 3
Psychosocial predictors of nonadherence to phosphate binding medication assessed by two or more studies.
0 1 2 3 4 5 6 7 8 9 10
Coping style
Anxiety/ depression
Knowledge
Family dynamics
Social support
Health locus of control
Personality 
Health beliefs
No. studies assessing each possible predictor of nonadherence
Not significant
Significant (p<.05)Page 7 of 10
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disagreements within the family [30] and lack of clear
family structure [31] were associated with low adherence
to phosphate binding medication. It is interesting that
whilst marital status/living arrangements alone were not
often associated with adherence, patients' perceptions of
the actual support they received and the quality of their
family relationships were more likely to be associated
with adherence. This is consistent with findings in the
broader social support literature that suggest that it is the
quality rather than quantity of social support that is
important in predicting mental and physical health out-
comes [32].
Four of the eight studies exploring personality as a predic-
tor of adherence to medication found significant results.
Personality traits associated with nonadherence included
low conscientiousness [14], high cynical hostility [33],
and being expedient, venturesome, experimental and
lacking self control [34].
Findings of studies looking at knowledge as a predictor of
nonadherence were mixed. Two out of four studies found
an association between knowledge of the purpose of the
regimen and phosphate levels [20,22]. However, the other
two studies found no relationship between knowledge of
treatment instructions and adherence to phosphate bind-
ing medication [26,35]. Knowledge might be a prerequi-
site for adherence behaviour but the presence of
knowledge alone may not bring about change in behav-
iour.
Methodological limitations of the studies reviewed
Several methodological limitations of the studies were
noted. These related to the definition and measurement of
nonadherence and the study design and sampling.
Adherence assessment methods
A variety of methods of assessing adherence were utilised
in the studies, including tablet counts, electronic monitor-
ing, patient self-report, health care professionals' reports
and serum phosphorus levels. Each method has its own
limitations, as discussed in a recent review of adherence,
compliance and concordance [5]. Serum phosphorus was
the most frequently used indicator of phosphate binder
adherence (79% studies). This can be problematic as it
reflects not only adherence to phosphate binding medica-
tion but also adherence to diet restrictions and dialysis
attendance. It has also been suggested that serum phos-
phorus levels can be affected by 'residual renal function,
urine output, co-morbid illnesses, hypercatabolism, nutri-
tional status, hormonal and acid base status, type and
intensity of dialytic treatment' [36], highlighting the lack
of specificity of this measure. Where studies used more
than one method of measuring adherence, rates of nonad-
herence and predictors of nonadherence varied depend-
ing on the adherence measure used [3,22,29]. This makes
it very difficult to accurately estimate the levels of nonad-
herence in the renal dialysis population.
Definitions of nonadherence
Definitions of nonadherence were inconsistent. Serum
phosphorus levels that were considered acceptable ranged
from 4.5 mg/dl [37] to 7.5 mg/dl [18] and this was
reflected in the reported rates of nonadherence, with the
study adopting the highest cut-off reporting the lowest
rates of nonadherence (22%, [18]), and the study adopt-
ing the lowest cut-off reporting one of the highest rates of
nonadherence (68%, [37]). Similarly, there was variation
in the level of adherence that was considered acceptable in
studies using self report measures of nonadherence, with
definitions of nonadherence ranging from 'ever missing a
dose' [38] to 'missing more than 20% of doses' [3]. More
research is necessary to determine the level of adherence
to phosphate binding medication required to prevent neg-
ative health outcomes.
Composite measures of adherence
Eight studies combined adherence to phosphate binding
medication with adherence to other parts of the treatment
regimen (e.g. attendance at dialysis, adherence to diet and
fluid restrictions) for the analysis [28-31,34,39-41]. Peo-
ple may have different levels of adherence for different
parts of the treatment regimen and therefore adherence to
the individual components should ideally be considered
in isolation. Indeed, studies that did assess adherence to
different parts of the regimen separately not only reported
different levels of adherence to the different aspects of
treatment but also found that different factors predicted
adherence to different parts of the regimen [12-
15,18,21,22,26,27,33,35,42-48].
Study design
Only three studies utilised a prospective design
[14,27,28], with the remainder using a cross sectional
study design. Whilst cross-sectional studies enable the
identification of associations between variables, prospec-
tive studies are required to determine causal links between
potential predictor variables and adherence.
Sample size
Many studies had small sample sizes, with a third includ-
ing less than 50 people and 6 studies (18%) reporting
sample sizes of 25 or less. Only one study included a
power calculation [17] and it is likely that many of the
other studies would not have had the power to detect pre-
dictors of nonadherence. It is therefore possible that
actual predictors of nonadherence remain undetected.
Future research should ensure sample sizes are largePage 8 of 10
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of nonadherence, should they exist.
Health care system bias
The vast majority of the studies were conducted in the
United States of America (79%). It is possible that the
health care system in the United States has unique charac-
teristics that could influence adherence (e.g. prescription
charges, private health insurance). It is therefore not pos-
sible to generalise the results to all health care systems and
there is a need for further research outside of the United
States.
Conclusion
Nonadherence to phosphate binding medication is a seri-
ous problem; studies report that 22–74% patients are
nonadherent with their phosphate binding medication,
with the variation attributable to differences in the defini-
tion and measurement of nonadherence.
Demographic and clinical factors are not consistently
associated with nonadherence to phosphate binding
medication, with the exception of age (older patients are
more likely to be adherent). However issues such as regi-
men complexity, which are likely to be important deter-
minants of adherence, have not been fully explored and
should be considered in future research.
Across studies, psychosocial factors appear to be the most
promising predictors of nonadherence, including
patients' beliefs about their treatment and their perceived
social support. However, limitations in research design
and study power create the need for further methodologi-
cally sound studies to identify the key beliefs influencing
nonadherence to phosphate binders as a basis for the
development of interventions to facilitate motivation,
informed choice and appropriate adherence.
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